TY - JOUR
T1 - The Effects of Mobile Phone Radiofrequency Electromagnetic Fields on β-Amyloid-Induced Oxidative Stress in Human and Rat Primary Astrocytes
AU - Ts, Andre
AU - Saliev, Timur
AU - Abzhanova, Elvira
AU - Turgambayeva, Anel
AU - Kaiyrlykyzy, Aiym
AU - Akishev, Mars
AU - Saparbayev, Samat
AU - Umbayev, Bauyrzhan
AU - Askarova, Sholpan
N1 - Funding Information:
The work was funded through the grants of the Ministry of Education and Science of the Republic of Kazakhstan №№ 0115RK00342 and AP05133266 .
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Amyloid beta peptide (Aβ) is implicated in the development of pathological reactions associated with Alzheimer's disease (AD), such as oxidative stress, neuro-inflammation and death of brain cells. Current pharmacological approaches to treat AD are not able to control the deposition of Aβ and suppression of Aβ-induced cellular response. There is a growing body of evidence that exposure to radiofrequency electromagnetic field (RF-EMF) causes a decrease of beta-amyloid deposition in the brains and provides cognitive benefits to Alzheimer's Tg mice. Herein, we investigated the effects of mobile phone radiofrequency EMF of 918 MHz on reactive oxygen species (ROS) formation, mitochondrial membrane potential (MMP), activity of NADPH-oxidase, and phosphorylation of p38MAPK and ERK1/2 kinases in human and rat primary astrocytes in the presence of Aβ 42 and H 2 O 2 . Our data demonstrate that EMF is able to reduce Aβ 42 - and H 2 O 2 -induced cellular ROS, abrogate Aβ₄₂-induced production of mitochondrial ROS and the co-localization between the cytosolic (p47-phox) and membrane (gp91-phox) subunits of NADPH oxidase, while increasing MMP, and inhibiting H 2 O 2 –induced phosphorylation of p38MAPK and ERK1/2 in primary astrocytes. Yet, EMF was not able to modulate alterations in the phosphorylation state of the MAPKs triggered by Aβ 42 . Our findings provide an insight into the mechanisms of cellular and molecular responses of astrocytes on RF-EMF exposure and indicate the therapeutic potential of RF-EMF for the treatment of Alzheimer's disease.
AB - Amyloid beta peptide (Aβ) is implicated in the development of pathological reactions associated with Alzheimer's disease (AD), such as oxidative stress, neuro-inflammation and death of brain cells. Current pharmacological approaches to treat AD are not able to control the deposition of Aβ and suppression of Aβ-induced cellular response. There is a growing body of evidence that exposure to radiofrequency electromagnetic field (RF-EMF) causes a decrease of beta-amyloid deposition in the brains and provides cognitive benefits to Alzheimer's Tg mice. Herein, we investigated the effects of mobile phone radiofrequency EMF of 918 MHz on reactive oxygen species (ROS) formation, mitochondrial membrane potential (MMP), activity of NADPH-oxidase, and phosphorylation of p38MAPK and ERK1/2 kinases in human and rat primary astrocytes in the presence of Aβ 42 and H 2 O 2 . Our data demonstrate that EMF is able to reduce Aβ 42 - and H 2 O 2 -induced cellular ROS, abrogate Aβ₄₂-induced production of mitochondrial ROS and the co-localization between the cytosolic (p47-phox) and membrane (gp91-phox) subunits of NADPH oxidase, while increasing MMP, and inhibiting H 2 O 2 –induced phosphorylation of p38MAPK and ERK1/2 in primary astrocytes. Yet, EMF was not able to modulate alterations in the phosphorylation state of the MAPKs triggered by Aβ 42 . Our findings provide an insight into the mechanisms of cellular and molecular responses of astrocytes on RF-EMF exposure and indicate the therapeutic potential of RF-EMF for the treatment of Alzheimer's disease.
KW - Alzheimer's disease
KW - astrocytes
KW - electromagnetic field
KW - oxidative stress
KW - β-amyloid
UR - http://www.scopus.com/inward/record.url?scp=85064170610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064170610&partnerID=8YFLogxK
U2 - 10.1016/j.neuroscience.2019.03.058
DO - 10.1016/j.neuroscience.2019.03.058
M3 - Article
C2 - 30953670
AN - SCOPUS:85064170610
SN - 0306-4522
VL - 408
SP - 46
EP - 57
JO - Neuroscience
JF - Neuroscience
ER -